Article

5 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 66, n° 6
pages e201-e208 (juin 2012)
Doi : 10.1016/j.jaad.2011.02.015
accepted : 15 February 2011
JAAD Online

Neuropeptide Y expression in cutaneous melanoma
 

Yolanda Gilaberte, MD, PhD a, c, , M. Jose Roca, RN b, M. Dolores Garcia-Prats, MD, PhD b, Carmen Coscojuela, MD a, M. Dolores Arbues, RN b, Jesús J. Vera-Alvarez, MD, PhD b
a Department of Dermatology, San Jorge Hospital, Huesca, Spain 
b Department of Pathology, San Jorge Hospital, Huesca, Spain 
c Health Science Institute of Aragon, Zaragoza, Spain 

Correspondence to: Yolanda Gilaberte, MD, PhD, Department of Dermatology, San Jorge Hospital, Av. Martínez de Velasco, 54, 22004 Huesca, Spain.
Abstract
Background

Neuropeptide Y (NPY) is widely found in the nervous system and has a role in numerous physiologic processes. In addition, NPY receptors are expressed in neuroendocrine tumors, breast cancer, prostate cancer, kidney cancer, and some types of sarcomas. Different neuropeptides, particularly ⍺-melanocyte-stimulating hormone (MSH), seem to play a role in the pathogenesis of melanoma.

Objective

We sought to analyze the expression of NPY in cutaneous melanoma, its association with clinical and histologic features, and its correlation with ⍺-MSH.

Methods

This was an observational study of the immunohistochemical expression of NPY and ⍺-MSH in tissue samples of cutaneous melanomas, different types of melanocytic nevi, and melanoma metastases diagnosed from 2004 to 2008 in San Jorge Hospital, Huesca, Spain.

Results

A total of 184 lesions were studied: 49 primary cutaneous melanomas, 12 melanoma metastases (9 cutaneous and 3 lymphatic), and 123 melanocytic nevi. Immunostaining revealed that levels of NPY and ⍺-MSH were significantly higher in melanomas than in melanocytic nevi (P < .001). Melanoma metastases were negative for both neuropeptides. Nodular melanomas showed the highest median percentage of NPY positive cells (75% [20-95]) followed by superficial spreading melanoma (25% [2-92]), whereas lentigo maligna were negative (0% [0-0]). Significant, direct associations between NPY expression and vertical growth (P  = .0141) and presence of metastasis (P  = .0196) were observed. NPY and ⍺-MSH were positively correlated in cutaneous melanoma (0.49, P < .001).

Limitations

The sample size of melanomas was not very large.

Conclusion

Our study demonstrates that NPY is significantly expressed in melanomas, especially the nodular type, being associated with invasiveness independently of proliferative markers such as thickness, ulceration, and mitotic index.

The full text of this article is available in PDF format.

Key words : immunochemistry, ⍺-melanocyte-stimulating hormone, melanocytic nevus, melanoma, melanoma invasiveness, melanoma metastasis, neuropeptide Y



 Supported by the Department of Science, Technology, and University of the Government of Aragon, Spain (Research Group B85).
 Conflicts of interest: None declared.
 Reprints not available from the authors.



© 2011  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline